Physician profile

Alison Dzwonczyk Early

Ophthalmology · Blue Ash, OH

NPI 1457771834

$69,230.40

in general payments reported to CMS, 2019-2025

33 companies · $41K in 2025

The $41K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).

See the full distribution for Ophthalmology

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$50,508.41
Food and Beverage$5,478.50
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$5,200.00
Travel and Lodging$3,901.13
Gift$20.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Rxsight INC $21,728.04 2022-2025 Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge
Alcon Vision LLC $10,934.65 2019-2025 Centurion, Clareon, Hydrus Microstent
Bausch & Lomb Americas INC. $10,536.29 2022-2025 Vyzulta, Stellaris, Totalvisc
Beaver-Visitec International, INC. $6,600.00 2024-2025
Tarsus Pharmaceuticals, INC. $5,490.80 2024-2025 Xdemvy
Harrow Eye, LLC $3,018.02 2024 Iheezo, Triesence
Johnson & Johnson Surgical Vision, INC. $2,653.78 2021-2025 Tecnis Simplicity, Tecnis Iol, Veritas Vision System
Lensar, INC. $1,744.84 2023-2024 Lensar Laser System
Carl Zeiss Meditec USA, INC. $1,734.64 2024-2025
Ocular Therapeutix, INC. $1,722.44 2022-2023 Dextenza
Nordic Pharma, INC. $480.15 2025 Lacrifill
Abbvie INC. $394.34 2022-2025 Ozurdex, Durysta
Carl Zeiss Meditec, INC. $325.14 2019-2025 Veracity Surgical
Allergan, INC. $320.90 2020-2022
Glaukos Corporation $238.24 2024-2025 Idosetr, Idose
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Ivantis, INC $222.56 2019-2021
Sight Sciences, INC. $204.37 2022-2024 Omni Surgical System
Novartis Pharmaceuticals Corporation $140.18 2020-2023
Biotissue Holdings INC. $133.29 2023-2024
Thea Pharma INC. $115.49 2023
Rayner Intraocular Lenses Limited $70.92 2025 Rayone Emv, Rayone Spheric, Rayone Aspheric
Kala Pharmaceuticals, INC. $64.36 2019-2022
Astellas Pharma US INC $47.35 2023
Aerie Pharmaceuticals, INC. $45.16 2019-2020
Dompe US, INC. $38.22 2022-2023 Oxervate
Alimera Sciences, INC. $37.90 2021-2023 Iluvien
Bausch & Lomb, A Division of Bausch Health US, LLC $37.86 2019
Horizon Therapeutics Plc $36.71 2023 Tepezza
Lombart Brothers, INC. $30.26 2019
Apellis Pharmaceuticals, INC. $27.02 2024 Syfovre
Mallinckrodt Hospital Products INC. $21.70 2024 Acthar
Haag-Streit USA, INC. $20.99 2023
Tearlab Corp $13.79 2023 Tearlab Osmolarity System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$4,455.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alison Dzwonczyk Early

$69,230.40

in general payments reported 2019-2025

Years
2019-2025
Top company
Rxsight INC
Context
The $41K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).

https://glasscript.com/doctor/4398060/alison-dzwonczyk-early

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.